论文部分内容阅读
目的探讨雌激素受体α的变异体ER-α36在人乳腺浸润性导管癌中的表达及其与临床分期、淋巴结转移、ER-α66、孕激素受体(PR)、表皮生长因子受体2(Her2)的关系。方法应用免疫组织化学SP法,检测33例乳腺浸润性导管癌组织ER-α36的表达,并与此组患者术后病检采用SP法检测的ER-α66、PR及Her2的表达进行相关分析。结果 ER-α36、ER-α66、Her2和PR在33例人乳腺浸润性导管癌中的阳性率分别为66.7%、51.5%、45.5%和60.6%。ER-α36的阳性表达率与ER-α66、PR、Her2、临床分期无明显相关性(P均>0.05)。ER-α36的表达与淋巴结转移呈负相关(rs=-0.368,P<0.05)。结论 ER-α36在多数人乳腺浸润性导管癌中表达。ER-α36表达与ER-α66、PR、Her2无相关性。
Objective To investigate the expression of ER-α36, a variant of estrogen receptor α, in invasive ductal carcinoma of the human breast and its relationship with clinical stage, lymph node metastasis, ER-α66, progesterone receptor (PR), epidermal growth factor receptor 2 (Her2) relationship. Methods Immunohistochemical SP method was used to detect the expression of ER-α36 in 33 cases of invasive ductal carcinoma of the breast. The expression of ER-α66, PR and Her2 were detected by SP method. Results The positive rates of ER-α36, ER-α66, Her2 and PR in 33 cases of invasive ductal carcinoma of human breast were 66.7%, 51.5%, 45.5% and 60.6% respectively. The positive expression rate of ER-α36 had no significant correlation with clinical stage of ER-α66, PR, Her2 (all P> 0.05). The expression of ER-α36 was negatively correlated with lymph node metastasis (rs = -0.368, P <0.05). Conclusion ER-α36 is expressed in most human invasive ductal carcinomas. ER-α36 expression and ER-α66, PR, Her2 no correlation.